Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.96
-1.6%
$4.47
$3.42
$8.14
$278.82M1.941.63 million shs664,250 shs
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$1.63
+14.0%
$1.41
$1.03
$2.57
$325.67M1.221.53 million shs2.44 million shs
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$3.00
-1.0%
$3.26
$1.42
$4.66
$267.01M0.79917,695 shs1.38 million shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$1.42
+5.2%
$1.03
$0.72
$6.24
$91.68M1.35543,147 shs3.63 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-2.33%+9.80%+18.59%-23.87%-28.00%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
+1.42%+2.88%+3.62%-37.00%-25.13%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-8.46%-4.11%+0.66%-15.60%+302,999,900.00%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
+23.85%+1.50%+39.30%0.00%-70.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4215 of 5 stars
0.02.00.00.02.40.80.6
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
2.4339 of 5 stars
3.71.00.00.02.72.50.6
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
2.7466 of 5 stars
3.61.00.00.03.33.30.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.4359 of 5 stars
4.53.00.00.02.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
3.33
Buy$10.50544.17% Upside
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.14
Buy$18.60520.00% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.00
Buy$14.25903.52% Upside

Current Analyst Ratings Breakdown

Latest INZY, ATYR, ATAI, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/13/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/10/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/8/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/19/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/14/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/12/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$24.00 ➝ $12.00
3/11/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$30.00 ➝ $23.00
3/11/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/11/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $15.00
3/10/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00 ➝ $7.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.87$0.19 per share26.35$8.18 per share0.61
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$308K1,057.36N/AN/A$1.47 per share1.11
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$235K1,136.22N/AN/A$1.54 per share1.95
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$2.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0599.2211.27N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%N/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%N/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$71.17M-$1.63N/AN/AN/AN/A-88.42%-57.02%N/A

Latest INZY, ATYR, ATAI, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/7/2025Q1 2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.19-$0.17+$0.02-$0.17N/AN/A
3/17/2025Q4 2024
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million
3/13/2025Q4 2024
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
N/AN/AN/AN/AN/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.14
5.81
5.81
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
0.02
5.41
5.41
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.51
7.68
7.68

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
28.41%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
61.72%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
31.20%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.70%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
80199.80 million115.45 millionOptionable
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
5389.00 million80.84 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million57.05 millionOptionable

Recent News About These Companies

Inozyme announces JBMR Plus publication on ENPP1 deficiency
Inozyme Pharma (INZY) Gets a Buy from Bank of America Securities
Inozyme price target lowered to $12 from $24 at Raymond James
Inozyme reports FY24 EPS ($1.62), consensus ($1.51)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.96 -0.08 (-1.59%)
As of 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Atai Life Sciences stock logo

Atai Life Sciences NASDAQ:ATAI

$1.63 +0.20 (+13.99%)
As of 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atyr PHARMA stock logo

Atyr PHARMA NASDAQ:ATYR

$3.00 -0.03 (-0.99%)
As of 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$1.42 +0.07 (+5.19%)
As of 04:00 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.